FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023967416> ?p ?o ?g. }

• W2023967416 endingPage "1146" @default.
• W2023967416 startingPage "1146" @default.
• W2023967416 abstract "To evaluate the safety and efficacy of controlled-release physostigmine, an acetylcholinesterase inhibitor, in patients with probable AD of mild to moderate severity.A prospective, 24-week, randomized, multicenter, double-blind, parallel group study of patients was conducted. The study enrolled 475 patients at 24 sites. Patients met criteria for probable AD and were randomized to one of three arms: placebo, controlled-release (CR) physostigmine 30 mg daily, or CR physostigmine 36 mg daily. Dosage was escalated by a forced upward titration during the first 6 to 9 weeks of the trial, then maintained at a constant dose to 24 weeks. Primary outcome measures were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Clinician's Interview-Based Impression of Change-Plus with caregiver input (CIBIC+). Secondary outcome measures included the Clinical Global Impression of Change (CGIC), the Geriatric Evaluation by Relatives Rating Instrument, and an Instrumental Activities of Daily Living Scale.In an intent-to-treat population, the last observation carried forward analysis revealed a 2.9-point ADAS-Cog (p = 0.002) difference between physostigmine and placebo-treated patients for both dosages, and a 0.26 to 0.31-point difference on the CIBIC+ (p = 0.048). There were no significant differences on the secondary outcome measures except for a difference on the CGIC when analyzed by use of the Cochran-Mantel-Haenszel statistic (p = 0.014). There were significant increases in gastrointestinal side effects including nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain for patients on either dose of physostigmine, resulting in a high dropout rate. Agitation was decreased significantly. There was no evidence of cardiac rhythm disturbance or liver function abnormalities.CR physostigmine enhanced cognitive and global function. It is relatively safe for the treatment of cognitive dysfunction secondary to AD. However, in light of the gastrointestinal side effects, a lower starting dose and a flexible titration schedule might lead to a more favorable adverse event profile in the clinical arena." @default.
• W2023967416 created "2016-06-24" @default.
• W2023967416 creator A5043899684 @default.
• W2023967416 creator A5061934117 @default.
• W2023967416 creator A5070895359 @default.
• W2023967416 creator A5074410453 @default.
• W2023967416 creator A5091679924 @default.
• W2023967416 date "1999-04-01" @default.
• W2023967416 modified "2023-09-26" @default.
• W2023967416 title "A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease" @default.
• W2023967416 cites W1847168837 @default.
• W2023967416 cites W1953027527 @default.
• W2023967416 cites W1982064952 @default.
• W2023967416 cites W2007423989 @default.
• W2023967416 cites W2016107968 @default.
• W2023967416 cites W2016254753 @default.
• W2023967416 cites W2016659621 @default.
• W2023967416 cites W2032640715 @default.
• W2023967416 cites W2035986126 @default.
• W2023967416 cites W2037113350 @default.
• W2023967416 cites W2057679568 @default.
• W2023967416 cites W2067418199 @default.
• W2023967416 cites W2078146183 @default.
• W2023967416 cites W2104227586 @default.
• W2023967416 cites W2119062449 @default.
• W2023967416 cites W2128529067 @default.
• W2023967416 cites W2137103253 @default.
• W2023967416 cites W2155087576 @default.
• W2023967416 cites W2156220037 @default.
• W2023967416 cites W2187766730 @default.
• W2023967416 doi "https://doi.org/10.1212/wnl.52.6.1146" @default.
• W2023967416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10214735" @default.
• W2023967416 hasPublicationYear "1999" @default.
• W2023967416 type Work @default.
• W2023967416 sameAs 2023967416 @default.
• W2023967416 citedByCount "66" @default.
• W2023967416 countsByYear W20239674162013 @default.
• W2023967416 countsByYear W20239674162014 @default.
• W2023967416 countsByYear W20239674162015 @default.
• W2023967416 countsByYear W20239674162016 @default.
• W2023967416 countsByYear W20239674162020 @default.
• W2023967416 countsByYear W20239674162022 @default.
• W2023967416 crossrefType "journal-article" @default.
• W2023967416 hasAuthorship W2023967416A5043899684 @default.
• W2023967416 hasAuthorship W2023967416A5061934117 @default.
• W2023967416 hasAuthorship W2023967416A5070895359 @default.
• W2023967416 hasAuthorship W2023967416A5074410453 @default.
• W2023967416 hasAuthorship W2023967416A5091679924 @default.
• W2023967416 hasConcept C126322002 @default.
• W2023967416 hasConcept C142724271 @default.
• W2023967416 hasConcept C168563851 @default.
• W2023967416 hasConcept C197934379 @default.
• W2023967416 hasConcept C204243189 @default.
• W2023967416 hasConcept C204787440 @default.
• W2023967416 hasConcept C27081682 @default.
• W2023967416 hasConcept C2775910092 @default.
• W2023967416 hasConcept C2776000289 @default.
• W2023967416 hasConcept C2776663719 @default.
• W2023967416 hasConcept C2780580376 @default.
• W2023967416 hasConcept C2780852908 @default.
• W2023967416 hasConcept C2908647359 @default.
• W2023967416 hasConcept C42219234 @default.
• W2023967416 hasConcept C71924100 @default.
• W2023967416 hasConcept C99454951 @default.
• W2023967416 hasConceptScore W2023967416C126322002 @default.
• W2023967416 hasConceptScore W2023967416C142724271 @default.
• W2023967416 hasConceptScore W2023967416C168563851 @default.
• W2023967416 hasConceptScore W2023967416C197934379 @default.
• W2023967416 hasConceptScore W2023967416C204243189 @default.
• W2023967416 hasConceptScore W2023967416C204787440 @default.
• W2023967416 hasConceptScore W2023967416C27081682 @default.
• W2023967416 hasConceptScore W2023967416C2775910092 @default.
• W2023967416 hasConceptScore W2023967416C2776000289 @default.
• W2023967416 hasConceptScore W2023967416C2776663719 @default.
• W2023967416 hasConceptScore W2023967416C2780580376 @default.
• W2023967416 hasConceptScore W2023967416C2780852908 @default.
• W2023967416 hasConceptScore W2023967416C2908647359 @default.
• W2023967416 hasConceptScore W2023967416C42219234 @default.
• W2023967416 hasConceptScore W2023967416C71924100 @default.
• W2023967416 hasConceptScore W2023967416C99454951 @default.
• W2023967416 hasIssue "6" @default.
• W2023967416 hasLocation W20239674161 @default.
• W2023967416 hasLocation W20239674162 @default.
• W2023967416 hasOpenAccess W2023967416 @default.
• W2023967416 hasPrimaryLocation W20239674161 @default.
• W2023967416 hasRelatedWork W1973491965 @default.
• W2023967416 hasRelatedWork W2117568169 @default.
• W2023967416 hasRelatedWork W2132406120 @default.
• W2023967416 hasRelatedWork W2349236515 @default.
• W2023967416 hasRelatedWork W2372024866 @default.
• W2023967416 hasRelatedWork W2472682794 @default.
• W2023967416 hasRelatedWork W3128218392 @default.
• W2023967416 hasRelatedWork W4235127086 @default.
• W2023967416 hasRelatedWork W63739596 @default.
• W2023967416 hasRelatedWork W1940111014 @default.
• W2023967416 hasVolume "52" @default.
• W2023967416 isParatext "false" @default.
• W2023967416 isRetracted "false" @default.

• next